{"symbol":"REGN","fiscalQuarter":"Q2-2016","reportDate":"2016-08-04","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q2-2016","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 1.81%","keyNumbers":[{"metric":"EPS","actual":"$2.82","expected":"N/A","surprise":"+63.48%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted the strong performance in their key product lines.","They noted ongoing investments in research and development to drive future growth."],"summary":"Overall, management expressed confidence in the company's product pipeline. They emphasized their commitment to innovation despite market challenges."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's earnings report showed a significant beat on EPS, indicating strong profitability. However, the stock reacted negatively, declining by 1.81%. This could suggest that investors were looking for more comprehensive revenue details or future guidance, which were not provided.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q2 2016 earnings: EPS beat by 63.48%. Stock down 1.81%. Full breakdown."}}